Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy.
G J
GJ
Moyle
N E
NE
Buss
B G
BG
Gazzard
D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000209:etiology*; D008297:Male; D017035:Pravastatin / Q000008:administration & dosage* / Q000009:adverse effects; D014766:Viremia / Q000188:drug therapy
D000924:Anticholesteremic Agents; D017320:HIV Protease Inhibitors; D017035:Pravastatin